Benzofuran compounds for the treatment of hepatitis C virus infections

• US 8,927,593 B2
• Filed: 08/10/2012
• Issued: 01/06/2015
• Est. Priority Date: 08/19/2011
• Status: Expired due to Fees

• Current Assignee: Glaxo Group Limited (GSK plc)
• Original Assignee: Glaxo Group Limited (GSK plc)
• Inventors: Chong, Pek Yoke, Shotwell, John Brad
• Primary Examiner(s): CHONG, YONG SOO
• Application Number:
  US13/885,500
• Publication Number:
  US 20130237501A1
• Time in Patent Office: 879 Days
• Field of Search: 514/183, 514/449, 514/461, 514/468
• US Class Current: 514/449
• CPC Class Codes: A61K 31/34 having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• CPC Class Codes: A61K 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07D 307/85 attached in position 2
• CPC Class Codes: C07F 5/025 Boronic and borinic acid compounds
• CPC Class Codes: C07F 5/027 Organoboranes and organoborohydrides
• CPC Class Codes: C07F 5/04 Esters of boric acids

Abstract

The present invention features compounds of formula (I):

and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.

Claims

1. A compound having the formula:

2. A compound having the formula:

3. A pharmaceutically acceptable salt of a compound having the formula: